Scholarlink

<p>Graft versus host disease (GVHD) is a serious side effect of allogenic stem cell transplantation (allo-SCT). Anti-thymocyte globulin (ATG) reduces GVHD but raises the risk of infections following allo-SCT. Preventive therapy is recommended for cytomegalovirus (CMV), which is a major pathogen. Prophylactic administration of letermovir has shown a significant reduction in CMV reactivation. We hypothesized letermovir could reduce CMV reactivation and affect the outcome of allo-SCT. We retrospectively studied 88 patients who received allo-SCT with ATG for acute leukemia or myelodysplastic syndromes (MDS) from 2014 to 2022. The patients were divided into letermovir (<i>n</i> = 34) and non-letermovir (<i>n</i> = 54) groups. 3-year overall survival rates were 85% (95%Confidence interval [CI]: 67%-93%) and 47% (95%CI: 33%–60%) in the letermovir and non-letermovir groups, respectively (<i>p</i> &lt; 0.01). Non-relapse mortality rate was equivalent, and the relapse rate was 21% (95%CI: 9.0%-36%) vs. 47% (95%CI: 33%-60%) and significantly lower in the letermovir group (<i>p</i> = 0.015). The cumulative CMV reactivation incidence rates at day 100 were 5.9% (95%CI: 1.0%-17%) and 43% (29%-55%) in the letermovir and non-letermovir groups (<i>p</i> = 0.012). These findings suggest letermovir helped the suppression of CMV reactivation and improved the outcome of allo-SCT with ATG by lowering relapse.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Letermovir improves the outcome of allogenic stem cell transplantation with anti-thymocyte globulin against acute leukemia and myelodysplastic syndromes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Shuto Negishi,
  • Kotaro Miyao,
  • Fumiya Ohara,
  • Kenta Motegi,
  • Hiroya Wakabayashi,
  • Hitomi Sawa,
  • Yuichiro Inagaki,
  • Masashi Sawa

摘要

Graft versus host disease (GVHD) is a serious side effect of allogenic stem cell transplantation (allo-SCT). Anti-thymocyte globulin (ATG) reduces GVHD but raises the risk of infections following allo-SCT. Preventive therapy is recommended for cytomegalovirus (CMV), which is a major pathogen. Prophylactic administration of letermovir has shown a significant reduction in CMV reactivation. We hypothesized letermovir could reduce CMV reactivation and affect the outcome of allo-SCT. We retrospectively studied 88 patients who received allo-SCT with ATG for acute leukemia or myelodysplastic syndromes (MDS) from 2014 to 2022. The patients were divided into letermovir (n = 34) and non-letermovir (n = 54) groups. 3-year overall survival rates were 85% (95%Confidence interval [CI]: 67%-93%) and 47% (95%CI: 33%–60%) in the letermovir and non-letermovir groups, respectively (p < 0.01). Non-relapse mortality rate was equivalent, and the relapse rate was 21% (95%CI: 9.0%-36%) vs. 47% (95%CI: 33%-60%) and significantly lower in the letermovir group (p = 0.015). The cumulative CMV reactivation incidence rates at day 100 were 5.9% (95%CI: 1.0%-17%) and 43% (29%-55%) in the letermovir and non-letermovir groups (p = 0.012). These findings suggest letermovir helped the suppression of CMV reactivation and improved the outcome of allo-SCT with ATG by lowering relapse.